Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog

Harsha Prasada Lashkari, Ruth Nash, Assunta Albanese, Bruce Okoye, Robert Millar, Kathy Pritchard-Jones

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.

Original languageEnglish
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
Publication statusPublished - 01-06-2013

Fingerprint

Gonadotropin-Releasing Hormone
Sertoli-Leydig Cell Tumor
Leuprolide
LHRH Receptors
Recurrence
Genetic Predisposition to Disease
Ovarian Neoplasms
Therapeutics
Maintenance
Drug Therapy
Mutation
Androblastoma of ovary
Neoplasms
Pleuropulmonary blastoma

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Lashkari, Harsha Prasada ; Nash, Ruth ; Albanese, Assunta ; Okoye, Bruce ; Millar, Robert ; Pritchard-Jones, Kathy. / Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6.
@article{c861800bf2f641f2bcecb19d69661954,
title = "Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog",
abstract = "Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.",
author = "Lashkari, {Harsha Prasada} and Ruth Nash and Assunta Albanese and Bruce Okoye and Robert Millar and Kathy Pritchard-Jones",
year = "2013",
month = "6",
day = "1",
doi = "10.1002/pbc.24382",
language = "English",
volume = "60",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog. / Lashkari, Harsha Prasada; Nash, Ruth; Albanese, Assunta; Okoye, Bruce; Millar, Robert; Pritchard-Jones, Kathy.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 01.06.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog

AU - Lashkari, Harsha Prasada

AU - Nash, Ruth

AU - Albanese, Assunta

AU - Okoye, Bruce

AU - Millar, Robert

AU - Pritchard-Jones, Kathy

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.

AB - Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84876437926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876437926&partnerID=8YFLogxK

U2 - 10.1002/pbc.24382

DO - 10.1002/pbc.24382

M3 - Article

C2 - 23193086

AN - SCOPUS:84876437926

VL - 60

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -